Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF): 2022-2025

Historic Depreciation & Amortization (CF) for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $156,000.

  • Phathom Pharmaceuticals' Depreciation & Amortization (CF) fell 18.32% to $156,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $698,000, marking a year-over-year decrease of 11.31%. This contributed to the annual value of $795,000 for FY2024, which is 38.26% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Depreciation & Amortization (CF) of $156,000 as of Q3 2025, which was down 9.30% from $172,000 recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $214,000 for Q1 2024, and its period low was $121,000 during Q3 2023.
  • Over the past 3 years, Phathom Pharmaceuticals' median Depreciation & Amortization (CF) value was $177,000 (recorded in 2025), while the average stood at $170,455.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first plummeted by 30.86% in 2023, then spiked by 60.16% in 2024.
  • Quarterly analysis of 4 years shows Phathom Pharmaceuticals' Depreciation & Amortization (CF) stood at $168,000 in 2022, then rose by 10.12% to $185,000 in 2023, then grew by 4.32% to $193,000 in 2024, then dropped by 18.32% to $156,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $156,000 for Q3 2025, versus $172,000 for Q2 2025 and $177,000 for Q1 2025.